Immix Biopharma
IMMX
67 hedge funds and large institutions have $127M invested in Immix Biopharma in 2025 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 5 closing their positions.
2,105% more capital invested
Capital invested by funds: $5.78M → $127M (+$122M)
720% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 5
183% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 6
116% more funds holding
Funds holding: 31 → 67 (+36)
63.02% more ownership
Funds ownership: 9.59% → 72.62% (+63%)
48% less call options, than puts
Call options by funds: $225K | Put options by funds: $436K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$16.1M |
| 2 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$12.3M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$10.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$7.92M |
| 5 |
Millennium Management
New York
|
+$6.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IW
Imprint Wealth
Mount Pleasant,
South Carolina
|
-$195K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$59.5K |
| 3 |
TW
TritonPoint Wealth
Chevy Chase,
Maryland
|
-$51.3K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$30.9K |
| 5 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$24.9K |
IMMX Hedge Fund Activity: Q4 2025 in Review
67 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q4 2025, worth a combined $127M — up 2,105% from $5.78M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new IMMX positions and 5 closed out — a net gain of 36 holders — while 17 added to existing stakes and 6 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $16.1M. The largest seller was Imprint Wealth, cutting an estimated $195K.
- 67 institutional investors held Immix Biopharma (IMMX) as of Q4 2025, up from 31 in Q3 2025.
- Funds reported $127M of Immix Biopharma stock for Q4 2025, up 2,105% quarter-over-quarter.
- 41 funds opened new Immix Biopharma positions in Q4 2025 and 5 closed out, a net change of +36 holders.
- The largest Immix Biopharma buyer in Q4 2025 was Janus Henderson Group, an estimated $16.1M added.
- The largest Immix Biopharma seller in Q4 2025 was Imprint Wealth, an estimated $195K sold.
Based on aggregated 13F filings for Q4 2025.